Furthermore, Jiang et al. showed that the combined serum neuronal exosome-associated α-syn and clusterin outperform any previously reported blood-based assay or CSF total or pathogenic α-syn in predicting PD from atypical parkinsonism in clinical and prodromal PD [131], while studies by Ohmichi et al. demonstrated the quantification of brain-derived EVs in plasma as a biomarker to diagnose PD [115]. The gene discussed is CLU; the disease is Parkinson disease.